Botulinum toxin production
The company specializes in researching, developing, producing, and manufacturing botulinum toxin.
Source: LinkedIn company description · Retrieved October 13, 2026
OBIGEN Pharma is a Taiwan biotech startup specializing in botulinum toxin research, development, production, and manufacturing.
OBIGEN Pharma was established in 2020 and is a subsidiary of OBI Pharma. OBIGEN states that its type A botulinum toxin OBI-858 originates from an API plant in Zhubei and a sterile drug product plant in Tainan.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company specializes in researching, developing, producing, and manufacturing botulinum toxin.
Source: LinkedIn company description · Retrieved October 13, 2026
The company actively forms international partnerships to launch its toxin globally.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026 and September 29, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.